Background
Calcium and magnesium levels in the blood are important for blood clotting and may affect how brain bleeding (intracerebral hemorrhage or ICH) worsens. This study aimed to maintain specific calcium and magnesium levels for three days after patients were admitted to the hospital.
Methods
This study was done at multiple hospitals from 2019 to 2022. It included adults aged 18-80 with acute ICH who did not need surgery. Patients were randomly divided into two groups: one received treatment to maintain calcium and magnesium levels, while the other did not. The main goal was to see if the bleeding in the brain increased in the first three days.
Results
Out of 354 patients, 105 completed the study. There were no significant differences in the amount of bleeding between the two groups on days two and three. However, some factors like the initial Glasgow coma scale score and hemoglobin levels were linked to changes in bleeding. On the third day, magnesium levels at admission were related to the increase in bleeding, but calcium levels were not.
Conclusion
Higher magnesium levels at admission were connected to increased bleeding in patients with acute ICH. While magnesium might not be a direct treatment, it could help identify patients who need strategies to prevent worsening bleeding.
Opportunities Based on Trial Data
Clinics can use this information to set clear goals for monitoring calcium and magnesium levels in ICH patients. This can help in developing better treatment plans.
Measurable Outcomes
Establish specific targets for administering calcium and magnesium to ensure patient safety and effective treatment.
AI Tools for Clinical Needs
Select AI solutions that are tailored to monitor and manage the treatment of calcium and magnesium levels in patients with ICH.
Implementation Steps
Begin with a pilot project to track results and the impact of AI tools in managing ICH treatment based on the trial findings.
Contact Us for AI Solutions in Medical Management
For more information, reach out to us:
